Ginsenoside Rg3-induced EGFR/MAPK pathway deactivation inhibits melanoma cell proliferation by decreasing FUT4/LeY expression

International Journal of Oncology

Volumn 46, Issue 4, 2015, Pages 1667-1676

  Shan, Xiu ^a   Aziz, Faisal ^a   Tian, Li Li ^a   Wang, Xiao Qi ^b   Yan, Qiu ^a   Liu, Ji Wei ^a  

^a DALIAN MEDICAL UNIVERSITY   (China)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Cell proliferation; Fucosyltransferase IV; Lewis Y; Melanoma; Rg3

Indexed keywords

CARBOHYDRATE ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR; FUCOSYLTRANSFERASE; FUCOSYLTRANSFERASE IV; GINSENOSIDE RG 3; LEWIS Y; MITOGEN ACTIVATED PROTEIN KINASE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BLOOD GROUP LEWIS SYSTEM; CD15 ANTIGEN; FUT4 PROTEIN, HUMAN; GINSENOSIDE; LEWIS Y ANTIGEN;

A375 CELL LINE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER SIZE; CELL PROLIFERATION; CELL VIABILITY; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; ENZYME INACTIVATION; FUCOSYLATION; GENE SILENCING; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MALE; MELANOMA; MOUSE; MTT ASSAY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; WESTERN BLOTTING; ANIMAL; BLOOD GROUP LEWIS SYSTEM; DRUG EFFECTS; DRUG SCREENING; GENETICS; METABOLISM; NUDE MOUSE; SKIN NEOPLASMS; TUMOR CELL LINE;

ANIMALS; ANTIGENS, CD15; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; FUCOSYLTRANSFERASES; GINSENOSIDES; HUMANS; LEWIS BLOOD-GROUP SYSTEM; MALE; MAP KINASE SIGNALING SYSTEM; MELANOMA; MICE; MICE, NUDE; SKIN NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84923105992     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2015.2886     Document Type: Article

References (38)

1. IVES NJ, STOWE RL, LORIGAN P and WHEATLEY K: Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: A meta-analysis of 18 trials involving 2, 621 patients. J Clin Oncol 25: 5426-5434, 2007.
2. BALCH CM, GERSHENWALD JE, SOONG SJ, et al: Final version of 2009 AJCC melanoma staging and classifcation. J Clin Oncol 27: 6199-6206, 2009.
3. MENZIES AM and LON GV: Recent advances in melanoma systemic therapy, BRAF inhibitors, CTLA4 antibodies and beyond. Eur J Cancer 49: 3229-3241, 2013.
4. MA C and ARMSTRONG AW: Severe adverse events from the treatment of advanced melanoma: A systematic review of severe side effects associated with ipilimumab, vemu-rafenib, interferon alfa-2b, dacarbazine and interleukin-2. J Dermatolog Treat 25: 401-408, 2014.
5. MENAA F: Latest approved therapies for metastatic melanoma: What comes next? J Skin Cancer 1: 1-10, 2013.
6. ZHANG S, ZHANG HS, CORDON-CARDO C, REUTER VE, SINGHAL AK, LIOYD KO and LIVINGSTON PO: Selection of tumor antigens as targets for immune attack using immunohistochemistry: II. Blood group-related antigens. Int J Cancer 73: 50-56, 1997.
7. + hema-topoietic progenitors but absent on mature lymphocytes. Glycobiology 11: 677-683, 2001.
8. ESCREVENTE C, MACHADO E, BRITO C, REIS CA, STOECK A, RUNZ S, MARMÉ A, ALTEVOGT P and COSTA J: Different expression levels of alpha3/4 fucosyltransferases and Lewis determinants in ovarian carcinoma tissues and Cell lines. Int J Oncol 29: 557-566, 2006.
9. ZHANG Z, SUN P, LIU J, FU L and YAN Q: Suppression of FUT1/FUT4 expression by siRNA inhibits tumor growth. Biochim Biophys Acta 1783: 287-296, 2008.
10. WANG YF, LIU JJ, LIN B, WANG CZ, LI Q, LIU S, YAN L, ZHANG S and IWAMORI M: Study on the expression and clinical signifcances of Lewis y antigen and integrin αv, β3 in epithelial ovarian tumors. Int J Mol Sci 12: 3409-3421, 2011.
11. KUO CH, CHEN PK, CHANG BI, SUNG MC, SHI CS, LEE JS, CHANG CF, SHI JY and WU HL: The recombinant lectin-like domain of thrombomodulin inhibits angiogenesis through interaction with Lewis Y antigen. Blood 119: 1302-1313, 2012.
12. GAO J, HU ZH, LIU JJ, LIU DW, WANG Y, CAI M, ZHANG D, TAN M and LIN B: Expression of CD147 and Lewis y antigen in ovarian Cancer and their relationship to drug resistance. Med Oncol 31: 920-929, 2014.
13. HU ZH, GAO J, LIU B, et al: High expression of Lewis y antigen and CD44 is correlated with resistance to chemotherapy in epithelial ovarian cancers. PLoS One 8: E57250, 2013.
14. b with a novel monoclonal antibody 692/29. PLoS One 8: E54892, 2013.
15. ZANDI R, LARSEN AB, ANDERSE P, STOCKHAUSEN MT and POULSEN HS: Mechanism for oncogenic activation of the epidermal growth factor receptor. Cell Signal 19: 2013-2023, 2007.
16. WESTON BW, NAIR RP, LARSEN RD and LOWE JB: Isolation of a novel human alpha (1, 3)-fucosyltransferase Gene and molecular comparison to the human Lewis blood group alpha (1, 3/1, 4) fucosyltransferase gene. Syntenic, homologous, nonallelic genes encoding enzymes with distinct acceptor substrate specifcities. J Biol Chem 267: 4152-4160, 1992.
17. WESTON BW, SMITH PL, KELLY RJ and LOWE JB: Molecular cloning of a fourth member of a human alpha (1, 3)-fucosyltransferase Gene family. Multiple homologous sequences that determine expression of the Lewis x, sialyl Lewis x, and difucosylsialyl Lewis x epitopes. J Biol Chem 267: 24575-24584, 1992.
18. PETRETTI T, SCHULZE B, SCHLAG PM and KEMMNER W: Altered mRNA expression of glycosyltransferases in human gastric carcinomas. Biochim Biophys Acta 1428: 209-218, 1999.
19. ITO H, HIRAIWA N, KANNAQI R, et al: Altered mRNA expression of specifc molecular species of fucosyl-and sialyl-transferases in human colorectal Cancer tissues. Int J Cancer 71: 556-564, 1997.
20. OGAWA J, INOUE H and KOIDE S: Expression of alpha-1, 3-fucosyl-transferase type IV and VII genes is related to poor prognosis in lung cancer. Cancer Res 56: 325-329, 1996.
21. LI HY, TONG SM, LIU JW, HAN L, HOU H, YAN Q and WANG XQ: Differential fucosyltransferase IV expression in squamous carcinoma cells is regulated by promoter methylation. Cell Mol Biol Lett 17: 206-216, 2012.
22. YANG X, ZHANG Z, JIA S, LIU Y, WANG X and YAN Q: Overexpression of fucosyltransferase IV in A431 Cell line increases Cell proliferation. Int J Biochem Cell Biol 39: 1722-1730, 2007.
23. PARK EH, KIM YJ, KANG KS, et al: Stereo specifc Anticancer effects of ginsenoside Rg3 epimers isolated from heat-processed American ginseng on human gastric Cancer cell. J Ginseng Res 38: 22-27, 2014.
24. CHEN XP, QIAN LL, HONG JH and CHEN JH: Ginsenoside Rg3 inhibits CXCR4 expression and related migrations in a breast Cancer Cell line. Int J Clin Oncol 16: 519-523, 2011.
25. LEE SY, KIM GT, ROH SH, SONG JS, KIM HJ, HONG SS, KWON SW and PARK JH: Proteomic analysis of the anti-cancer effect of 20S-Ginsenoside Rg3 in human colon Cancer Cell lines. Biosci Biotechnol Biochem 73: 811-816, 2009.
26. ZHANG C, LIU LJ, YU Y, CHEN B, TANG C and LI X: Antitumor effects of ginsenoside Rg3 on human hepatocellular carcinoma cells. Mol Med Rep 5: 1295-1298, 2012.
27. KIM JW, JUNG SY, KWON YH, LEE JH, LEE YM, LEE BY and KWON SM: Ginsenoside Rg3 attenuates tumor angiogenesis via inhibiting bioactivities of endothelial progenitor cells. Cancer Biol Ther 13: 504-515, 2012.
28. KIM YJ, CHOI WI, KO H, et al: Stereo specific effects of ginsenoside 20-Rg3 inhibits TGF1-induced epithelial-mesen-chymal transition and suppresses lung Cancer migration, invasion and anoikis resistance. Toxicology 322: 23-33, 2014.
29. Kim DG, Jung KH, Kim YS, et al: 20 (S)-Ginsenoside Rg3 is a novel inhibitor of autophagy and sensitizes hepatocellular carcinoma to doxorubicin. Oncotarget 5: 4438-4451, 2014.
30. HE BC, GAO JL, ZHOU BQ, et al: Ginsenoside Rg3 inhibits colorectal tumor growth through the down-regulation of Wnt/β-catenin signaling. Int J Oncol 38: 437-445, 2011.
31. KIM SM, LEE SY, YUK DY, MOON DC, CHOI SS, KIM Y, HAN SB, OH KW and HONG JT: Inhibition of NF-κB by ginsenoside Rg3 enhances the susceptibility of colon Cancer cells to docetaxel. Arch Pharm Res 32: 755-765, 2009.
32. YANG XS, LIU S, LIU YJ, LIU JW, LIU TJ, WANG XQ and YAN Q: Overexpression of fucosyltransferase IV promotes A431 Cell proliferation through activating MAPK and PI3K/Akt signaling pathways. J Cell Physiol 225: 612-619, 2010.
33. YANG XS, LIU YJ, LIU JW, WANG XQ and YAN Q: Cyclo-phosphamide-induced apoptosis in A431 cells is inhibited by fucosyltransferase IV. J Cell Biochem 112: 1376-1383, 2011.
34. CIOLCZYK-WIERZBICKA D, BODZIOCH M, GIL D, ZMUDZINSKA D, DEMBINSKA-KIEC A and LAIDLER P: Expression of fucosyltrans-ferases contributes to melanoma invasive phenotype. Med Chem 3: 418-424, 2007.
35. AZUMA Y, ITO M, TANIGUCHI A and MATSUMOTO K: Expression of Cell surface Lewis X and Y antigens and FUT4 mRNA is increased in Jurkat cells undergoing apoptosis. Biochim Biophys Acta 1672: 157-163, 2004.
36. MADJD Z, PARSONS T, WATSON N, SPENDLOVE I, ELLIS I and DURRANT LG: High expression of Lewisy/b antigens is associated with decreased survival in lymph node negative breast carcinomas. Breast Cancer Res 7: 780-787, 2005.
37. HU ZH, GAO S, LIN B, et al: Elevated levels of Lewis Y and integrin α5β1 correlate with chemotherapeutic drug resistance in epithelial ovarian carcinoma. Int J Mol Sci 13: 15588-15600, 2012.
38. FARHANH, SCHUSTER C, KIRCHEIS R, et al: Inhibition of xenograft tumor growth and down-regulation of ErbB receptors by an antibody directed against Lewis Y antigen. J Pharmacology Exp T her 319: 1459-1466, 2006.